dasabuvir 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antivirals RNA polymerase (NS5B) inhibitors 4914 1132935-63-7

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • dasabuvir sodium monohydrate
  • dasabuvir
  • dasabuvir sodium
  • exviera
  • ABT-333
Dasabuvir is a non-nucleoside inhibitor of the HCV RNA-dependent RNA polymerase encoded by the NS5B gene, which is essential for replication of the viral genome. In a biochemical assay, dasabuvir inhibited a panel of genotype 1a and 1b NS5B polymerases. Based on drug resistance mapping studies of HCV genotypes 1a and 1b, dasabuvir targets the palm domain of the NS5B polymerase, and is therefore referred to as a non-nucleoside NS5B-palm polymerase inhibitor.
  • Molecular weight: 493.58
  • Formula: C26H27N3O5S
  • CLOGP: 4.07
  • LIPINSKI: 0
  • HAC: 8
  • HDO: 2
  • TPSA: 104.81
  • ALOGS: -5.79
  • ROTB: 5

  • Status: OFM

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.50 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Hosey CM, Chan R, Benet LZ
Vd (Volume of distribution) 2.13 L/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.01 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 5.70 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Nov. 20, 2014 EMA AbbVie Ltd
Dec. 19, 2014 FDA ABBVIE INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Jaundice 398.45 28.33 131 4420 26298 50574275
Hyperbilirubinaemia 339.59 28.33 92 4459 9478 50591095
Hepatic failure 250.78 28.33 98 4453 32185 50568388
Ascites 217.01 28.33 91 4460 35770 50564803
Blood bilirubin increased 189.44 28.33 80 4471 31958 50568615
Hepatocellular carcinoma 155.11 28.33 36 4515 1963 50598610
Hepatic encephalopathy 122.05 28.33 42 4509 9594 50590979
Asthenia 91.69 28.33 127 4424 318915 50281658
Hepatic cirrhosis 87.76 28.33 39 4512 17538 50583035
Renal impairment 82.14 28.33 62 4489 75599 50524974
Anaemia 73.14 28.33 101 4450 252355 50348218
Vomiting 69.28 28.33 137 4414 460621 50139952
Child-Pugh-Turcotte score increased 67.67 28.33 9 4542 11 50600562
Hepatorenal syndrome 53.60 28.33 15 4536 1728 50598845
Drug ineffective 50.70 28.33 7 4544 819326 49781247
Varices oesophageal 46.64 28.33 15 4536 2774 50597799
Encephalopathy 44.19 28.33 31 4520 33680 50566893
Yellow skin 42.66 28.33 13 4538 2016 50598557
Acute hepatic failure 39.90 28.33 22 4529 15655 50584918
Portal vein thrombosis 37.41 28.33 12 4539 2200 50598373
Hepatic cancer 36.55 28.33 13 4538 3262 50597311
Renal failure 32.75 28.33 44 4507 106589 50493984
Nausea 30.97 28.33 135 4416 705263 49895310

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hepatocellular carcinoma 224.10 29.47 68 3914 6970 29563575
Ascites 216.20 29.47 103 3879 36516 29534029
Renal impairment 189.51 29.47 124 3858 81209 29489336
Hyperbilirubinaemia 156.49 29.47 63 3919 14871 29555674
Jaundice 138.73 29.47 71 3911 29225 29541320
Hepatic failure 125.41 29.47 68 3914 31444 29539101
Blood bilirubin increased 118.06 29.47 67 3915 33826 29536719
Hepatic cirrhosis 114.58 29.47 50 3932 14394 29556151
Hepatic encephalopathy 106.24 29.47 46 3936 12989 29557556
Drug interaction 48.11 29.47 91 3891 197294 29373251
Oesophageal varices haemorrhage 44.93 29.47 16 3966 2686 29567859
Anaemia 42.13 29.47 87 3895 200864 29369681
Gastric varices haemorrhage 41.67 29.47 9 3973 232 29570313
Asthenia 32.62 29.47 82 3900 215168 29355377
Yellow skin 30.54 29.47 11 3971 1907 29568638
Encephalopathy 29.51 29.47 28 3954 31015 29539530

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Jaundice 455.46 26.16 187 8182 48325 64442038
Hyperbilirubinaemia 449.82 26.16 149 8220 21056 64469307
Ascites 392.38 26.16 181 8188 61820 64428543
Hepatocellular carcinoma 326.55 26.16 94 8275 8309 64482054
Hepatic failure 323.35 26.16 153 8216 55241 64435122
Renal impairment 258.45 26.16 180 8189 134837 64355526
Blood bilirubin increased 241.19 26.16 127 8242 57426 64432937
Hepatic encephalopathy 200.01 26.16 82 8287 20984 64469379
Hepatic cirrhosis 172.98 26.16 79 8290 26219 64464144
Anaemia 103.88 26.16 180 8189 378500 64111863
Asthenia 101.57 26.16 191 8178 427853 64062510
Hepatorenal syndrome 81.99 26.16 27 8342 3719 64486644
Child-Pugh-Turcotte score increased 79.82 26.16 12 8357 32 64490331
Yellow skin 78.69 26.16 25 8344 3074 64487289
Oesophageal varices haemorrhage 66.94 26.16 23 8346 3606 64486757
Drug interaction 64.84 26.16 144 8225 361939 64128424
Drug ineffective 62.84 26.16 16 8353 840231 63650132
Encephalopathy 53.62 26.16 51 8318 58768 64431595
Off label use 49.30 26.16 11 8358 632795 63857568
Portal vein thrombosis 49.27 26.16 20 8349 4971 64485392
Vomiting 46.70 26.16 167 8202 550950 63939413
Varices oesophageal 45.36 26.16 19 8350 5111 64485252
Acute hepatic failure 41.06 26.16 31 8338 26081 64464282
Alanine aminotransferase increased 39.10 26.16 67 8302 138964 64351399
Gastric varices haemorrhage 38.83 26.16 9 8360 334 64490029
Renal failure 36.70 26.16 76 8293 181612 64308751
Hepatic neoplasm 32.69 26.16 13 8356 3064 64487299
Ocular icterus 32.49 26.16 15 8354 5083 64485280
Upper gastrointestinal haemorrhage 31.06 26.16 30 8339 35190 64455173
Decreased appetite 30.68 26.16 93 8276 281196 64209167
Hepatic cancer 29.89 26.16 16 8353 7432 64482931
Haematemesis 28.86 26.16 33 8336 46966 64443397
Bilirubin conjugated increased 26.71 26.16 13 8356 4955 64485408
Procalcitonin 26.26 26.16 4 8365 12 64490351

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC J05AP09 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIVIRALS FOR SYSTEMIC USE
DIRECT ACTING ANTIVIRALS
Antivirals for treatment of HCV infections
ATC J05AP52 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIVIRALS FOR SYSTEMIC USE
DIRECT ACTING ANTIVIRALS
Antivirals for treatment of HCV infections
FDA MoA N0000190113 Breast Cancer Resistance Protein Inhibitors
FDA EPC N0000191257 Hepatitis C Virus Non-Nucleoside NS5B Palm Polymerase Inhibitor
FDA MoA N0000191258 RNA Replicase Inhibitors
FDA MoA N0000191272 UGT1A1 Inhibitors
CHEBI has role CHEBI:36044 antiviral drugs
CHEBI has role CHEBI:85180 nonnucleoside hepatitis C virus polymerase inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Chronic hepatitis C indication 128302006




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.38 acidic
pKa2 9.01 acidic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
EQ 200MG BASE;8.33MG;50MG;33.33MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** VIEKIRA XR ABBVIE INC N208624 July 22, 2016 DISCN TABLET, EXTENDED RELEASE ORAL 8501238 Sept. 17, 2028 USE OF DASABUVIR TO INHIBIT VIRAL REPLICATION FOR THE TREATMENT OF HCV INFECTION.
EQ 250MG BASE;12.5MG, 75MG, 50MG VIEKIRA PAK (COPACKAGED) ABBVIE INC N206619 Dec. 19, 2014 DISCN TABLET ORAL 9139536 Nov. 9, 2028 TREATMENT OF HCV INFECTION USING DASABUVIR
EQ 200MG BASE;8.33MG;50MG;33.33MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** VIEKIRA XR ABBVIE INC N208624 July 22, 2016 DISCN TABLET, EXTENDED RELEASE ORAL 9139536 Nov. 9, 2028 TREATMENT OF HCV INFECTION USING DASABUVIR
EQ 250MG BASE;12.5MG, 75MG, 50MG VIEKIRA PAK (COPACKAGED) ABBVIE INC N206619 Dec. 19, 2014 DISCN TABLET ORAL 8501238 Dec. 19, 2028 USE OF DASABUVIR TO INHIBIT VIRAL REPLICATION FOR THE TREATMENT OF HCV INFECTION.
EQ 250MG BASE;12.5MG, 75MG, 50MG VIEKIRA PAK (COPACKAGED) ABBVIE INC N206619 Dec. 19, 2014 DISCN TABLET ORAL 8188104 May 17, 2029 USE OF DASABUVIR TO INHIBIT VIRAL REPLICATION FOR THE TREATMENT OF HCV INFECTION.
EQ 200MG BASE;8.33MG;50MG;33.33MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** VIEKIRA XR ABBVIE INC N208624 July 22, 2016 DISCN TABLET, EXTENDED RELEASE ORAL 8188104 May 17, 2029 USE OF DASABUVIR TO INHIBIT VIRAL REPLICATION FOR THE TREATMENT OF HCV INFECTION.
EQ 250MG BASE;12.5MG, 75MG, 50MG VIEKIRA PAK (COPACKAGED) ABBVIE INC N206619 Dec. 19, 2014 DISCN TABLET ORAL 8642538 Sept. 10, 2029 TREATMENT OF HCV INFECTION USING PARITAPREVIR
EQ 200MG BASE;8.33MG;50MG;33.33MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** VIEKIRA XR ABBVIE INC N208624 July 22, 2016 DISCN TABLET, EXTENDED RELEASE ORAL 8642538 Sept. 10, 2029 TREATMENT OF HCV INFECTION USING PARITAPREVIR
EQ 250MG BASE;12.5MG, 75MG, 50MG VIEKIRA PAK (COPACKAGED) ABBVIE INC N206619 Dec. 19, 2014 DISCN TABLET ORAL 9006387 June 10, 2030 TREATMENT OF HCV INFECTION USING OMBITASVIR
EQ 200MG BASE;8.33MG;50MG;33.33MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** VIEKIRA XR ABBVIE INC N208624 July 22, 2016 DISCN TABLET, EXTENDED RELEASE ORAL 9006387 June 10, 2030 TREATMENT OF HCV INFECTION USING OMBITASVIR
EQ 250MG BASE;12.5MG, 75MG, 50MG VIEKIRA PAK (COPACKAGED) ABBVIE INC N206619 Dec. 19, 2014 DISCN TABLET ORAL 9044480 April 10, 2031 TREATMENT OF HCV INFECTION USING PARITAPREVIR
EQ 200MG BASE;8.33MG;50MG;33.33MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** VIEKIRA XR ABBVIE INC N208624 July 22, 2016 DISCN TABLET, EXTENDED RELEASE ORAL 9044480 April 10, 2031 TREATMENT OF HCV INFECTION USING PARITAPREVIR
EQ 200MG BASE;8.33MG;50MG;33.33MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** VIEKIRA XR ABBVIE INC N208624 July 22, 2016 DISCN TABLET, EXTENDED RELEASE ORAL 10201584 May 17, 2032 TREATMENT OF HCV INFECTION USING DASABUVIR/OMBITASVIR/PARITAPREVIR/RITONAVIR FIXED DOSE COMBINATION
EQ 250MG BASE;12.5MG, 75MG, 50MG VIEKIRA PAK (COPACKAGED) ABBVIE INC N206619 Dec. 19, 2014 DISCN TABLET ORAL 8466159 Sept. 4, 2032 TREATMENT OF HCV INFECTION USING PARITAPREVIR, OMBITASVIR, RITONAVIR, AND DASABUVIR WITH RIBAVIRIN.
EQ 250MG BASE;12.5MG, 75MG, 50MG VIEKIRA PAK (COPACKAGED) ABBVIE INC N206619 Dec. 19, 2014 DISCN TABLET ORAL 8492386 Sept. 4, 2032 TREATMENT OF HCV INFECTION USING PARITAPREVIR, OMBITASVIR, RITONAVIR, AND DASABUVIR, WITHOUT RIBAVIRIN
EQ 250MG BASE;12.5MG, 75MG, 50MG VIEKIRA PAK (COPACKAGED) ABBVIE INC N206619 Dec. 19, 2014 DISCN TABLET ORAL 8680106 Sept. 4, 2032 TREATMENT OF HCV INFECTION USING PARITAPREVIR, OMBITASVIR, RITONAVIR, AND DASABUVIR WITH RIBAVIRIN.
EQ 250MG BASE;12.5MG, 75MG, 50MG VIEKIRA PAK (COPACKAGED) ABBVIE INC N206619 Dec. 19, 2014 DISCN TABLET ORAL 8685984 Sept. 4, 2032 TREATMENT OF HCV INFECTION USING PARITAPREVIR, OMBITASVIR, RITONAVIR, AND DASABUVIR, WITHOUT RIBAVIRIN
EQ 200MG BASE;8.33MG;50MG;33.33MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** VIEKIRA XR ABBVIE INC N208624 July 22, 2016 DISCN TABLET, EXTENDED RELEASE ORAL 8466159 Sept. 4, 2032 TREATMENT OF HCV INFECTION USING PARITAPREVIR, OMBITASVIR, RITONAVIR, AND DASABUVIR WITH RIBAVIRIN.
EQ 200MG BASE;8.33MG;50MG;33.33MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** VIEKIRA XR ABBVIE INC N208624 July 22, 2016 DISCN TABLET, EXTENDED RELEASE ORAL 8492386 Sept. 4, 2032 TREATMENT OF HCV INFECTION USING PARITAPREVIR, OMBITASVIR, RITONAVIR, AND DASABUVIR, WITHOUT RIBAVIRIN
EQ 200MG BASE;8.33MG;50MG;33.33MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** VIEKIRA XR ABBVIE INC N208624 July 22, 2016 DISCN TABLET, EXTENDED RELEASE ORAL 8680106 Sept. 4, 2032 TREATMENT OF HCV INFECTION USING PARITAPREVIR, OMBITASVIR, RITONAVIR, AND DASABUVIR WITH RIBAVIRIN.
EQ 200MG BASE;8.33MG;50MG;33.33MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** VIEKIRA XR ABBVIE INC N208624 July 22, 2016 DISCN TABLET, EXTENDED RELEASE ORAL 8685984 Sept. 4, 2032 TREATMENT OF HCV INFECTION USING PARITAPREVIR, OMBITASVIR, RITONAVIR, AND DASABUVIR, WITHOUT RIBAVIRIN
EQ 250MG BASE;12.5MG, 75MG, 50MG VIEKIRA PAK (COPACKAGED) ABBVIE INC N206619 Dec. 19, 2014 DISCN TABLET ORAL 10201542 Oct. 18, 2033 TREATMENT OF HCV INFECTION USING DASABUVIR
EQ 250MG BASE;12.5MG, 75MG, 50MG VIEKIRA PAK (COPACKAGED) ABBVIE INC N206619 Dec. 19, 2014 DISCN TABLET ORAL 9629841 Oct. 18, 2033 TREATMENT OF HCV INFECTION USING DASABUVIR
EQ 200MG BASE;8.33MG;50MG;33.33MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** VIEKIRA XR ABBVIE INC N208624 July 22, 2016 DISCN TABLET, EXTENDED RELEASE ORAL 10105365 Jan. 2, 2035 TREATMENT OF HCV INFECTION USING DASABUVIR/OMBITASVIR/PARITAPREVIR/RITONAVIR FIXED DOSE COMBINATION
EQ 200MG BASE;8.33MG;50MG;33.33MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** VIEKIRA XR ABBVIE INC N208624 July 22, 2016 DISCN TABLET, EXTENDED RELEASE ORAL 9333204 Jan. 2, 2035 TREATMENT OF HCV INFECTION USING DASABUVIR/OMBITASVIR/PARITAPREVIR/RITONAVIR FIXED DOSE COMBINATION
EQ 200MG BASE;8.33MG;50MG;33.33MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** VIEKIRA XR ABBVIE INC N208624 July 22, 2016 DISCN TABLET, EXTENDED RELEASE ORAL 9744170 Jan. 2, 2035 TREATMENT OF HCV INFECTION USING DASABUVIR/OMBITASVIR/PARITAPREVIR/RITONAVIR FIXED DOSE COMBINATION

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Protein cereblon Cytosolic other Ki 5.33 CHEMBL
NS5B protein Enzyme EC50 8.74 CHEMBL

External reference:

IDSource
D10553 KEGG_DRUG
1456607-55-8 SECONDARY_CAS_RN
4034028 VANDF
CHEBI:85182 CHEBI
CHEMBL3137312 ChEMBL_ID
C588260 MESH_SUPPLEMENTAL_RECORD_UI
11270 IUPHAR_LIGAND_ID
9741 INN_ID
DB09183 DRUGBANK_ID
DE54EQW8T1 UNII
56640146 PUBCHEM_CID
1597381 RXNORM
30778 MMSL
31899 MMSL
d08322 MMSL
015829 NDDF
015830 NDDF
714104000 SNOMEDCT_US
714105004 SNOMEDCT_US
716018007 SNOMEDCT_US
725851005 SNOMEDCT_US
C3852512 UMLSCUI
CHEMBL3544985 ChEMBL_ID

Pharmaceutical products:

None